SGMO - Sangamo Therapeutics Inc Stock Price, Fair Value and News

$0.50+0.06 (+13.64%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SGMO Price Action

Last 7 days

8.7%

Last 30 days

-13.8%

Last 90 days

-5.7%

Trailing 12 Months

-76.7%

SGMO RSI Chart

SGMO Valuation

Market Cap

168.2M

Price/Earnings (Trailing)

-1.54

Price/Sales (Trailing)

5.12

EV/EBITDA

-1.31

Price/Free Cashflow

-2.03

SGMO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SGMO Fundamentals

SGMO Revenue

Revenue (TTM)

32.9M

Rev. Growth (Yr)

-98.82%

Rev. Growth (Qtr)

-96.83%

SGMO Earnings

Earnings (TTM)

-108.9M

Earnings Growth (Yr)

-427.31%

Earnings Growth (Qtr)

-74.77%

SGMO Profitability

EBT Margin

-332.63%

Return on Equity

-1.7K%

Return on Assets

-122.86%

Free Cashflow Yield

-49.37%

SGMO Investor Care

Shares Dilution (1Y)

61.27%

Diluted EPS (TTM)

-0.43

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	69.8M	81.7M	32.9M	0
2024	146.6M	117.0M	87.4M	57.8M
2023	241.0M	218.5M	201.4M	176.2M
2022	112.7M	114.2M	112.1M	111.3M
2021	131.4M	137.7M	108.5M	110.7M
2020	107.4M	111.4M	147.2M	118.2M
2019	79.9M	76.0M	74.4M	102.4M
2018	45.8M	58.9M	70.7M	84.5M
2017	18.9M	23.4M	32.4M	36.6M
2016	30.0M	25.3M	19.6M	19.4M
2015	51.2M	49.2M	45.4M	39.5M
2014	27.6M	31.1M	37.8M	45.9M
2013	23.0M	25.4M	26.2M	24.1M
2012	11.4M	14.4M	17.5M	21.7M
2011	16.4M	11.3M	10.3M	10.3M
2010	0	0	0	20.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

CEO	Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
WEBSITE	sangamo.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	478

Sangamo Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sangamo Therapeutics Inc? What does SGMO stand for in stocks?

SGMO is the stock ticker symbol of Sangamo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sangamo Therapeutics Inc (SGMO)?

As of Wed Dec 03 2025, market cap of Sangamo Therapeutics Inc is 168.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers.

Is Sangamo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SGMO is over valued or under valued. Whether Sangamo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sangamo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGMO.

What is Sangamo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SGMO's PE ratio (Price to Earnings) is -1.54 and Price to Sales (PS) ratio is 5.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sangamo Therapeutics Inc's stock?

In the past 10 years, Sangamo Therapeutics Inc has provided -0.252 (multiply by 100 for percentage) rate of return.